Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study.
Rossetti B, Gagliardini R, Sterrantino G, Colangeli V, Latini A, Colafigli M, Vignale F, Rusconi S, Di Biagio A, Orofino G, Mezzaroma I, Vullo V, Francisci D, Mastroianni C, Trezzi M, Canovari B, Lamonica S, Ciccullo A, Borghetti A, DʼArminio Monforte A, Di Giambenedetto S, De Luca A; for GUSTA trial study group. Rossetti B, et al. Among authors: colafigli m. J Acquir Immune Defic Syndr. 2019 May 1;81(1):e17-e21. doi: 10.1097/QAI.0000000000001986. J Acquir Immune Defic Syndr. 2019. PMID: 30789452 Free PMC article. Clinical Trial. No abstract available.
Interpretation systems for genotypic drug resistance of HIV-1.
De Luca A, Antinori A, Di Giambenedetto S, Cingolani A, Colafigli M, Perno CF, Cauda R. De Luca A, et al. Among authors: colafigli m. Scand J Infect Dis Suppl. 2003;106:29-34. doi: 10.1080/03008870310009623. Scand J Infect Dis Suppl. 2003. PMID: 15000579 Review.
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors.
Di Giambenedetto S, Bacarelli A, Pinnetti C, Colafigli M, Prosperi M, Gatti G, Cauda R, De Luca A. Di Giambenedetto S, et al. Among authors: colafigli m. Scand J Infect Dis. 2007;39(9):813-8. doi: 10.1080/00365540701367728. Scand J Infect Dis. 2007. PMID: 17701721
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy.
Marzocchetti A, Schwarz J, Di Giambenedetto S, Colafigli M, Bracciale L, Fabbiani M, Fantoni M, Trecarichi E, Cauda R, De Luca A. Marzocchetti A, et al. Among authors: colafigli m. AIDS Res Hum Retroviruses. 2011 Dec;27(12):1299-309. doi: 10.1089/aid.2010.0172. Epub 2011 Jun 20. AIDS Res Hum Retroviruses. 2011. PMID: 21595566
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group.
Svicher V, Alteri C, Montano M, D'Arrigo R, Andreoni M, Angarano G, Antinori A, Antonelli G, Allice T, Bagnarelli P, Baldanti F, Bertoli A, Borderi M, Boeri E, Bon I, Bruzzone B, Callegaro AP, Capobianchi MR, Carosi G, Cauda R, Ceccherini-Silberstein F, Clementi M, Chirianni A, Colafigli M, D'Arminio Monforte A, De Luca A, Di Biagio A, Di Nicuolo G, Di Perri G, Di Pietro M, Di Santo F, Fabeni L, Fadda G, Galli M, Gennari W, Ghisetti V, Giacometti A, Gori C, Gori A, Gulminetti R, Leoncini F, Maffongelli G, Maggiolo F, Manca G, Gargiulo F, Martinelli C, Maserati R, Mazzotta F, Meini G, Micheli V, Monno L, Mussini C, Narciso P, Nozza S, Paolucci S, Pal G, Parisi S, Parruti G, Pignataro AR, Pollicita M, Quirino T, Re MC, Rizzardini G, Santangelo R, Scaggiante R, Sterrantino G, Turriziani O, Vatteroni ML, Vecchi L, Viscoli C, Vullo V, Zazzi M, Lazzarini A, Perno CF; DIVA group. Svicher V, et al. Among authors: colafigli m. New Microbiol. 2012 Jan;35(1):17-25. Epub 2012 Jan 10. New Microbiol. 2012. PMID: 22378549 Free article.
87 results